Physician profile
Taufik E Kassis
NPI 1174545628
$7,914.35
in general payments reported to CMS, 2019-2025
45 companies · $721 in 2025
The $721 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $782 · 2021: $1,826 · 2022: $1,043 · 2023: $1,116 · 2024: $973 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,809.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,212.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,177.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $777.05 | 2020-2024 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $673.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $572.16 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $553.27 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $409.59 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.70 | 2019-2025 | Jardiance |
| Gilead Sciences, INC. | $339.53 | 2021-2025 | |
| Indivior INC. | $297.02 | 2019-2024 | Sublocade |
| Lilly USA, LLC | $147.75 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $106.91 | 2021-2024 | |
| Dexcom, INC. | $96.20 | 2024-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.97 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.44 | 2022-2025 | Caplyta |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taufik Kassis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.